welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer
Cancer Prevention Pharmaceuticals, Inc. (“CPP”) announced today the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to evaluate CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer.
The trial is funded by the National Cancer Institute (NCI) and run in collaboration with Keith T. Wilson, M.D., and Douglas R. Morgan, M.D., MPH, of Vanderbilt University School of Medicine, Vanderbilt University Medical Center, and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
-
Cancer Prevention Pharmaceuticals, Inc. and Tillotts Pharma AG Sign Licensing Agreement for CPP-1X/sulindac in Europ...Cancer Prevention Pharmaceuticals, Inc. ...
-
Low-Dose Dacarbazine-Doxorubicin Therapy Against Intra-Abdominal Desmoid TumorsIntra-abdominal desmoid tumor is a life-...
-
Regression of Colonic Adenomas After Treatment with Sulindac in Familial Adenomatous Polyposis: A Case with a 2-Year...Familial adenomatous polyposis (FAP) is ...
-
18F-FES PET/CT in Imaging Patients With Desmoid TumorsThis pilot clinical trial studies fluori...
-
Impact of a Hospital-based Register on the Management of Familial Adenomatous PolyposisColorectal cancer in familial adenomatou...
-
Anorectal Functional Outcome After Repeated Transanal Endoscopic MicrosurgeryAIM : To evaluate the status of anorecta...
-
Shattering Cancer with Resonant Frequencies: Anthony Holland at TEDx Skidmore Collegehttps://www.youtube.com/watch?v=1w0_kazb...